Presentation is loading. Please wait.

Presentation is loading. Please wait.

Feasibility and Potential Utility of Multicomponent Exhaled Breath Analysis for Predicting Development of Radiation Pneumonitis After Stereotactic Ablative.

Published byRoderick Smith Modified over 6 years ago

Similar presentations

Presentation on theme: "Feasibility and Potential Utility of Multicomponent Exhaled Breath Analysis for Predicting Development of Radiation Pneumonitis After Stereotactic Ablative."— Presentation transcript:

1 Feasibility and Potential Utility of Multicomponent Exhaled Breath Analysis for Predicting Development of Radiation Pneumonitis After Stereotactic Ablative Radiotherapy  Jayaji M. Moré, MS, Neville C.W. Eclov, BS, Melody P. Chung, BS, Jacob F. Wynne, BS, Joanne H. Shorter, PhD, David D. Nelson, PhD, Alexandra L. Hanlon, PhD, Robert Burmeister, PhD, Peter Banos, MD, Peter G. Maxim, PhD, Billy W. Loo, MD, PhD, Maximilian Diehn, MD, PhD  Journal of Thoracic Oncology  Volume 9, Issue 7, Pages (July 2014) DOI: /JTO Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Sample NO and CO expiration profiles before and after SABR for patients that did and did not develop radiation pneumonitis (RP). Before SABR measurement shown in blue and after SABR measurement shown in red. Final concentrations were calculated as mean over the final 3 seconds of expiration, using American Thoracic Society/ European Respiratory Society recommendations for standardized measurement of exhaled NO. (A) NO expiration profile in patient who developed RP. (B) CO expiration profile in patient who developed RP. (C) NO expiration profile in patient who did not develop RP. (D) CO expiration profile in patient who did not develop RP. Journal of Thoracic Oncology 2014 9, DOI: ( /JTO ) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Dot plots of baseline exhaled NO and CO concentrations for patients that did and did not develop RP. Bars show average values. A, Baseline exhaled NO concentrations. (B) Baseline exhaled CO concentrations. Current nonsmokers shown as filled circles and current smokers shown as open circles. Journal of Thoracic Oncology 2014 9, DOI: ( /JTO ) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Dot plots of average acute percent changes in exhaled NO and CO after SABR for patients that did and did not develop RP. Bars show average values. The independent samples t test was used to assess significance. A, average acute change in exhaled NO after SABR. (B) Average acute change in exhaled CO after SABR. Journal of Thoracic Oncology 2014 9, DOI: ( /JTO ) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Feasibility and Potential Utility of Multicomponent Exhaled Breath Analysis for Predicting Development of Radiation Pneumonitis After Stereotactic Ablative."

Similar presentations

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,
Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.
Stereotactic Body Radiotherapy for Lung Cancer: How Much Does it Really Cost?  Yolande Lievens, PhD, Caroline Obyn, MSc, Anne-Sophie Mertens, MSc, Dries.

Stereotactic Body Radiotherapy for Lung Cancer: How Much Does it Really Cost?  Yolande Lievens, PhD, Caroline Obyn, MSc, Anne-Sophie Mertens, MSc, Dries.
Brandon Stone, MD, Victor S. Mangona, MD, Matthew D

Brandon Stone, MD, Victor S. Mangona, MD, Matthew D
Two Classic Lyrics Joined by a Contemporary Tune—Environmental Pro-Carcinogen Exposure and Genetic Susceptibility in Lung Cancer Risk  Ping Yang, MD,

Two Classic Lyrics Joined by a Contemporary Tune—Environmental Pro-Carcinogen Exposure and Genetic Susceptibility in Lung Cancer Risk  Ping Yang, MD,
Impact of Race on Outcomes of Patients with Non-small Cell Lung Cancer

Impact of Race on Outcomes of Patients with Non-small Cell Lung Cancer
One in every 14 patients with early-stage lung cancer is not being treated!  Benny Weksler, MD, MBA  The Journal of Thoracic and Cardiovascular Surgery 

One in every 14 patients with early-stage lung cancer is not being treated!  Benny Weksler, MD, MBA  The Journal of Thoracic and Cardiovascular Surgery 
It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible  Alessandro Brunelli,

It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible  Alessandro Brunelli,
Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis  Matthew Koshy, MD, Renuka Malik,

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis  Matthew Koshy, MD, Renuka Malik,
ALK FISH and IHC: You Cannot Have One without the Other

ALK FISH and IHC: You Cannot Have One without the Other
Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D

Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D
Brenda G. Clark, PhD, Robert J

Brenda G. Clark, PhD, Robert J
Brandon Stone, MD, Victor S. Mangona, MD, Matthew D

Brandon Stone, MD, Victor S. Mangona, MD, Matthew D
Irinotecan-Cisplatin Therapy for Patients with Extensive-Stage Small Cell Lung Cancer: Use Patterns among American Medical Oncologists 2000–2006  Mark.

Irinotecan-Cisplatin Therapy for Patients with Extensive-Stage Small Cell Lung Cancer: Use Patterns among American Medical Oncologists 2000–2006  Mark.
Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K
NA  Journal of Thoracic Oncology 

NA  Journal of Thoracic Oncology 
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers
Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small-Cell Lung Cancer  Masatsugu Hamaji,

Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small-Cell Lung Cancer  Masatsugu Hamaji,
Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer  Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer  Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,
Use of Stereotactic Ablative Radiotherapy (SABR) in Non–Small Cell Lung Cancer Measuring More Than 5 cm  Hilâl Tekatli, MD, Saar van ’t Hof, MD, Esther.

Use of Stereotactic Ablative Radiotherapy (SABR) in Non–Small Cell Lung Cancer Measuring More Than 5 cm  Hilâl Tekatli, MD, Saar van ’t Hof, MD, Esther.

Similar presentations

Ads by Google